Celltrion Reports Positive Data For High-Concentration Adalimumab

Phase III Trials Cover Two Delivery Methods For CT-P17

 
• By Akriti Seth
  
Needle pen
Celltrion’s trials demonstrated the safety and efficacy of its high-concentration adalimumab biosimilar • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products